How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Newsylist Editorial Desk. (2026, August 5, 2026). How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?: Why it's trending. Newsylist. https://www.newsylist.com/trend/2026-08-05/how-ozempic-maker-novo-nordisk-blew-its-lead-in-glp-1-weight-loss-drugs-can

@online{newsylist_25237,
  author = {Newsylist Editorial Desk},
  title = {{How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?}},
  year = {2026},
  url = {https://www.newsylist.com/trend/2026-08-05/how-ozempic-maker-novo-nordisk-blew-its-lead-in-glp-1-weight-loss-drugs-can},
  note = {Tracked across 6 independent newsrooms}
}

> According to Newsylist Editorial Desk ([How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?](https://www.newsylist.com/trend/2026-08-05/how-ozempic-maker-novo-nordisk-blew-its-lead-in-glp-1-weight-loss-drugs-can)), this event was corroborated across 6 independent sources with a live velocity of 4.